Experience
Eli Lilly and Company
Genentech, Inc.
Successfully represented Lilly in post-grant review (PGR) proceeding relating to patent on IL-17A/F antibodies that had been asserted against Lilly’s blockbuster Taltz® pharmaceutical and in parallel district court litigation. Achieved institution of PGR, judgment in favor of petitioner, and dismissal of the district court case.
Eli Lilly and Company v. Genentech, Inc., PGR2019-00043, PTAB, Judges Mitchell, Paulraj, Cotta
Genentech, Inc. v. Eli Lilly and Company, 3:18-cv-01518, S.D. Cal., Judge Sammartino
Alzheimer's Institute of America, Inc. v. Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
Eli Lilly and Company
Eli Lilly and Co. v. Apotex Inc.
Eli Lilly and Company
Eli Lilly and Company v. Perrigo Co.
Eli Lilly and Company
Eli Lilly and Company v. Actavis Labs. UT Inc.
Eli Lilly and Company
Hospira, Inc. v. Eli Lilly and Co.
Eli Lilly and Co.
Eli Lilly and Company v. Sicor Pharmaceuticals, Inc.
Eli Lilly and Company
Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista®
Eli Lilly and Company
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Eli Lilly and Company
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.